| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Immunology [V. K., R. G. U., R. B., J. H. F.], Urology [R. G. U., R. B., A. C. N., J. H. F.], Experimental Therapeutics [V. K., R. B., J. H. F.], and Pathology [E. D. H.], The Cleveland Clinic Foundation, Cleveland, Ohio 44195, and Department of Urology, Division of Urologic Oncology, The New York Hospital, Cornell University Medical Center, New York, New York 10021 [N. H. B.]
The antitumor effect of immuno- and chemotherapeutic agents is executed through stimulation of apoptotic programs in susceptible cells. Apoptosis induced in tumor cells requires activation of members of the caspase family of proteases. Deficient expression or activation of caspases may account in part for the failure of many current anticancer therapies. However, recent studies suggest that cell death can proceed in the absence of caspases. We investigated the susceptibility of human renal cell carcinoma (RCC) lines to two distinct modes of cell death, apoptosis and necrosis. RCC lines displayed almost complete resistance to apoptosis in response to the intracellular zinc chelator, N,N,N'N'-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN), which instead induced dramatic accumulation of nonapoptotic necrotic cells. Conversely, TPEN was a potent inducer of apoptosis in caspase-competent normal kidney cells (NK-72) and Jurkat T lymphocytes. Resistance to apoptosis in RCC lines correlated with almost complete loss of caspase-3 expression and variable down-regulation of caspase-7, caspase-8, and caspase-10. These data may explain the resistance of RCC to drugs inducing apoptosis and have important consequences for further attempts to manipulate tumor cell death.
This article has been cited by other articles:
![]() |
Z. T. Schafer, A. B. Parrish, K. M. Wright, S. S. Margolis, J. R. Marks, M. Deshmukh, and S. Kornbluth Enhanced Sensitivity to Cytochrome c-Induced Apoptosis Mediated by PHAPI in Breast Cancer Cells Cancer Res., February 15, 2006; 66(4): 2210 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
P-Y Fong, W-C Xue, H Y S Ngan, P-M Chiu, K Y K Chan, S W Tsao, and A N Y Cheung Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study J. Clin. Pathol., February 1, 2006; 59(2): 179 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells Cancer Res., August 1, 2005; 65(15): 6891 - 6900. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mizutani, H. Nakanishi, K. Yamamoto, Y. N. Li, H. Matsubara, K. Mikami, K. Okihara, A. Kawauchi, B. Bonavida, and T. Miki Downregulation of Smac/DIABLO Expression in Renal Cell Carcinoma and Its Prognostic Significance J. Clin. Oncol., January 20, 2005; 23(3): 448 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. R. Fantin and P. Leder F16, a Mitochondriotoxic Compound, Triggers Apoptosis or Necrosis Depending on the Genetic Background of the Target Carcinoma Cell Cancer Res., January 1, 2004; 64(1): 329 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kudo, P. Rayman, C. Horton, M. K. Cathcart, R. M. Bukowski, M. Thornton, C. Tannenbaum, and J. H. Finke Gangliosides Expressed by the Renal Cell Carcinoma Cell Line SK-RC-45 Are Involved in Tumor-induced Apoptosis of T Cells Cancer Res., April 1, 2003; 63(7): 1676 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Uzzo, V. Kolenko, C. J. Froelich, C. Tannenbaum, L. Molto, A. C. Novick, N. H. Bander, R. Bukowski, and J. H. Finke The T Cell Death Knell: Immune-mediated Tumor Death in Renal Cell Carcinoma Clin. Cancer Res., October 1, 2001; 7(10): 3276 - 3281. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Datta, R. Nambudripad, S. Pal, M. Zhou, H. T. Cohen, and D. Mukhopadhyay Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer J. Biol. Chem., June 30, 2000; 275(27): 20700 - 20706. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |